Cifras del mercado farmacéutico global

Sales Through Retail Pharmacies (Twelve months to September 2010)*

NORTH AMERICA $242.2 billion up 4%
U.S.A. $223.0 billion up 4%
CANADA $19.2 billion up 5%

EUROPE (TOP 5) $108.4 billion up 2%
GERMANY $35.3 billion up 4%
FRANCE $28.5 billion up 0%
ITALY $16.2 billion up 1%
SPAIN $14.7 billion up 1%
UK $13.7 billion up 2%

JAPAN (including hospitals) $83.7 billion up 2%
CHINA (hospital) $31.1 billion up 23%
AUSTRALIA/NZ $9.3 billion up 6%

LATIN AMERICA (TOP 4) $34.2 billion

BRAZIL $16.7 billion up 20%
MEXICO $7.6 billion up 2%
VENEZUELA $6.1 billion up 30%
ARGENTINA $3.8 billion up 24%

The top 5 therapy classes at ATC3 level in the 12 months to September 2010 were:

1. C10A – Cholesterol & trigly. regulators
2. A2B - Antiulcerants
3. N5A - Antipsychotics
4. N6A – Antidepressants & mood stabilisers
5. C9C – Angioten-II Antag, Plain

The top 5 products in the 12 months to September 2010 were:

1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor

The top 5 corporations in the 12 months to September 2010 were:

1. Pfizer
2. Novartis
3. AstraZeneca
4. Merck & Co
5. GlaxoSmithKline